Detalhe da pesquisa
1.
Outcomes of a Phase II Study of Intraperitoneal Paclitaxel plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Ann Surg Oncol
; 29(13): 8597-8605, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36070113
2.
ASO Visual Abstract: Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Ann Surg Oncol
; 29(13): 8608-8609, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36207480
3.
Phase II study of trifluridine/tipiracil in metastatic breast cancers with or without prior exposure to fluoropyrimidines.
Eur J Cancer
; 193: 113311, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37717281
4.
Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer.
Thorac Cancer
; 13(22): 3152-3161, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36177913
5.
Serial Tumor Molecular Profiling of Newly Diagnosed HER2-Negative Breast Cancers During Chemotherapy in Combination with Angiogenesis Inhibitors.
Target Oncol
; 17(3): 355-368, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35699834
6.
Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer.
Clin Cancer Res
; 28(11): 2248-2256, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35363275